APE1氧化还原抑制剂通过抑制FGF2血管生成信号减轻病理性视网膜血管化
本研究在氧诱导视网膜病变(OIR)小鼠模型中评估APE1氧化还原抑制剂Refi-10对病理性视网膜新生血管(RNV)的治疗作用及机制。Refi-10显著减少病理性血管生成并改善RNV病变,机制上通过抑制APE1减轻炎症和血管生成,且不降低视网膜VEGF而通过抑制FGF2表达发挥作用。结果提名APE1和FGF2信号为有前景的治疗靶点,Refi-10可作为血管性视网膜病变的候选药物。
要点
- Refi-10在OIR小鼠中显著减少病理性血管生成并改善RNV病变。
- Refi-10不降低视网膜VEGF,而是通过抑制FGF2表达减轻RNV。
- APE1和FGF2信号被提名为血管性视网膜病变的潜在治疗靶点。
核心结论
- Refi-10通过抑制APE1氧化还原功能、下调FGF2表达来减轻病理性视网膜新生血管,不依赖降低VEGF。
- APE1和FGF2信号是有前景的治疗靶点,Refi-10可作为血管性视网膜病变的候选药物,提供VEGF抑制的替代或互补策略。
研究设计与样本
- 使用氧诱导视网膜病变(OIR)小鼠模型和APE1氧化还原抑制剂Refi-10研究APE1氧化还原功能在视网膜新生血管中的作用及Refi-10疗效。
- 对OIR视网膜进行转录组分析,鉴定与RNV及Refi-10介导改善相关的促血管生成因子和通路。
- 使用视网膜色素上皮(RPE)和人视网膜微血管内皮细胞(hRMECs)研究细胞机制及对Refi-10的反应。
主要发现
- Refi-10显著减少病理性血管生成并改善RNV病变。
- 机制研究表明Refi-10通过抑制APE1减轻炎症和血管生成。
- Refi-10在OIR中不降低视网膜VEGF,而是通过抑制成纤维细胞生长因子2(FGF2)表达来减轻RNV。
临床怎么用
- Refi-10可能作为血管性视网膜病变的候选药物,尤其针对抗VEGF抵抗或需减少反复眼内注射风险的情形。
- APE1和FGF2信号可作为替代或互补于VEGF抑制的治疗靶点进行进一步转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Retinal neovascular (RNVs) diseases are major causes of visual loss. Current first-line therapies for RNV primarily target VEGF. However, intrinsic or acquired resistance to anti-VEGF therapy, along with the risks associated with repeated intraocular injections, underscores the need for alternative targets and new therapeutic strategies. Apurinic/apyrimidinic endonuclease 1 (APE1) regulates transcription factors implicated in RNV. The purpose of this study was to evaluate APE1 as a therapeutic target, assess the potential of its redox inhibitor, Refi-10, as a drug candidate for vascular retinopathies, and elucidate underlying mechanisms. METHODS: An oxygen-induced retinopathy (OIR) mouse model and the APE1 redox inhibitor Refi-10 were used to investigate the contribution of APE1 redox function in retinopathy neovascularization and assess the therapeutic efficacy of Refi-10. Transcriptomic analysis of OIR retinas identified pro-angiogenic factors and pathways associated with RNV and Refi-10-mediated improvement. Retinal pigment epithelium (RPE) and human retinal microvascular endothelial cells (hRMECs) were used to investigate cellular mechanisms and responses to Refi-10. RESULTS: Refi-10 significantly reduced pathological angiogenesis and ameliorated RNV disease. Mechanistic studies showed that Refi-10 attenuated inflammation and angiogenesis via APE1 inhibition. Notably, Refi-10 did not decrease retinal VEGF in OIR but mitigated RNV by suppressing fibroblast growth factor 2 (FGF2) expression. CONCLUSIONS: These findings nominate APE1 and FGF2 signaling as promising therapeutic targets, and show that Refi-10 holds potential as a drug candidate for vascular retinopathies, offering an alternative or complementary approach to VEGF inhibition.
引用
- Yan C, Fu Q, Wang J, et al. An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling. Invest Ophthalmol Vis Sci. 2026. PMID: 41860321. doi:10.1167/iovs.67.3.47
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。